Update shared on22 Oct 2025
Analysts have raised their average price target for Harrow, citing increased confidence in the company's commercial execution and long-term revenue growth potential. Recent updates reflect new targets up to $74, compared to previous levels between $42 and $70.
Analyst Commentary
Recent analyst updates on Harrow highlight notable optimism about the company's growth trajectory and commercial strategy, while also underscoring a few areas of caution as the company scales its business.
Bullish Takeaways- Bullish analysts are increasing their price targets significantly, citing strengthened confidence in Harrow's long-term revenue and margin expansion potential.
- The company's expanding pipeline portfolio and clear commercial roadmap are viewed as key drivers supporting higher valuations.
- There is an expectation for material revenue contributions from underappreciated assets, such as recently added ophthalmic biosimilars. These contributions are expected to begin in 2026.
- Analysts anticipate Harrow's ability to scale its business rapidly. They project the potential for quarterly revenues to exceed $250 million by late 2027.
- Some analysts note lingering uncertainty around the commercial strategies for new biosimilars. They point to the need for more detailed guidance and execution clarity.
- Questions remain regarding the sustainability of recent sales growth, especially following shifts in pricing programs, such as the effect of VEVYE's new patient cost structure.
- Execution risk is flagged as Harrow integrates multiple new products and programs. This requires sustained operational excellence to fully realize projected growth.
What's in the News
- Harrow launched the Harrow Access for All (HAFA) program, expanding affordable access to its branded, generic, and compounded ophthalmic medications. The program will have a phased rollout through 2027 and will provide a centralized online portal for physicians and patients. (Product-Related Announcements)
- The Audit Committee of Harrow's Board of Directors dismissed Crowe LLP as independent auditor and appointed Deloitte & Touche LLP to audit the 2025 financial statements. (Auditor Changes)
- Harrow's Board adopted amended and restated company bylaws, revising officer titles and responsibilities and clarifying corporate governance practices. (Changes in Company Bylaws/Rules)
- The company reaffirmed revenue guidance for 2025, projecting revenue of over $280 million and targeting approximately $169 million in the second half of the year. (Corporate Guidance: New or Confirmed)
- Harrow recently held an Analyst and Investor Day to update stakeholders. (Analyst and Investor Day)
Valuation Changes
- Fair Value remains unchanged at $68.18 per share.
- Discount Rate is unchanged at 6.78%.
- Revenue Growth has marginally decreased from 39.997% to 39.996% per year.
- Net Profit Margin has slightly decreased, moving from 30.43% to 30.38%.
- Future P/E has risen slightly from 17.90x to 17.93x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.